The company noted that if PAMA cuts go into effect at the beginning of next year as scheduled, they would negatively impact its 2026 revenues by around $100 million.

The California-based firm said that its VeriClear EbV MARV Rapid Antigen Test will be used for the detection and differentiation of Ebola and Marburg virus infections.

Last week, readers were most interested in a story about alternatives to blood as sample types for diagnostic testing.

As the shutdown drags out, there could be delays in regulatory processes and payments for medical services as well as the ...

Researchers hope to soon commercialize a simple, inexpensive, and accessible screening test that uses taste as a detection ...

Regulatory burdens have raised the capital requirements for early-stage companies, causing many to do what would have been ...

The firm also reported a 3 percent increase in preliminary full-year 2025 revenues and announced the departure of its CFO.

A report that private equity firms and a group of banks were preparing bids for the firm drove up the price of Hologic's stock by as much as 4 percent on Thursday.

Having expanded access to quantitative hemoglobin variant testing in 40 countries, Hemex is now also setting its sights on the US and Europe.

Sebia sells electrophoresis instruments and protein-based IVDs for use in multiple myeloma as well as metabolic, autoimmune, and inflammatory conditions.